Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantationOTTO, G; HOFMANN, W. J; GAWECO, A. S et al.Transplantation proceedings. 1996, Vol 28, Num 6, pp 3210-3211, issn 0041-1345Conference Paper

BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejectionMUELLER, A. R; PLATZ, K.-P; STEINMÜLLER, T et al.Transplantation proceedings. 1996, Vol 28, Num 6, pp 3103-3105, issn 0041-1345Conference Paper

IL-2 Receptor antibody induction increases the risk for chronic rejection after liver transplantationLANGREHR, J. M; LOHMANN, R; STEINMÜLLER, T et al.Transplantation proceedings. 2001, Vol 33, Num 1-2, pp 1433-1434, issn 0041-1345Conference Paper

Anti-IL-2 receptor BT563 versus placebo : A randomized trial for induction therapy after liver transplantationGLANEMANN, M; LANGREHR, J. M; SETTMACHER, U et al.Transplantation proceedings. 1998, Vol 30, Num 5, pp 2159-2160, issn 0041-1345Conference Paper

A randomized trial comparing anti-interleukin-2 receptor antibody and placebo for immunosuppressive therapy after OLTLANGREHR, J. M; GLANEMANN, M; SCHLAG, H et al.Transplantation proceedings. 1998, Vol 30, Num 4, pp 1445-1446, issn 0041-1345Conference Paper